Fig. 6

Pharmacokinetics/pharmacodynamics of hOA-DN30. a Serum concentrations measured at different time points after single intravenous administration of hOA-DN30 (30 mg/kg) to NOD-SCID mice bearing or not EBC-1 tumors. Each point is the mean of quadruplicate values; bars represent SD. b Observed tumor volumes and predicted (Pr.) tumor growth curves after intravenous administrations of hOA-DN30 (5, 10, and 30 mg/kg 1xweek) to NOD-SCID mice bearing subcutaneous EBC-1 tumors. c Serum concentrations measured at different time points after single intravenous administration of hOA-DN30 (11 mg/kg) to Cynomolgus monkeys. Each point is the mean of triplicate values; bars represent SD